Johnson & Johnson (NYSE:JNJ) Shares Down 1.4% – Here’s Why

Johnson & Johnson (NYSE:JNJ) dropped 1.4% during mid-day trading on Wednesday . The company traded as low as $263.13 and last traded at $263.5160. Approximately 6,693,754 shares were traded during trading, a decline of 21% from the average daily volume of 8,463,563 shares. The stock had previously closed at $267.24.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J won FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF platform, which could support medtech revenue and reinforce the company’s innovation pipeline. Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
• Positive Sentiment: Recent commentary and analyst updates remain constructive, with Wall Street highlighting J&J’s stronger outlook, defensive earnings profile, and potential upside after the stock’s recent run. Johnson & Johnson Gains as Higher Outlook and Pre-Earnings Optimism Support Shares
• Neutral Sentiment: J&J is drawing attention as investors position for upcoming quarterly results, with the company’s raised full-year guidance and steady sales growth helping keep sentiment stable. Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Wednesday
• Negative Sentiment: One market note warned that J&J may be trading above fair value after its recent rally, and unusual put activity suggests some traders are hedging for a pullback. Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism
• Negative Sentiment: Unusual put option buying indicates that some investors believe the recent strength could fade, adding a cautious tone to trading in the stock. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JNJ. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research note on Wednesday, May 13th. Raymond James Financial upped their target price on Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Argus raised their price target on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Barclays lifted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 15th. Finally, Daiwa Securities Group increased their price objective on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $257.74.

Johnson & Johnson Trading Down 1.4%

The company has a market cap of $634.34 billion, a price-to-earnings ratio of 30.46, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The firm has a 50-day moving average price of $235.09 and a 200 day moving average price of $232.13. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Insiders Place Their Bets

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently made changes to their positions in the stock. White Wing Wealth Management bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $210,000. Victrix Investment Advisors grew its stake in Johnson & Johnson by 9.1% during the 2nd quarter. Victrix Investment Advisors now owns 28,068 shares of the company’s stock worth $7,129,000 after buying an additional 2,351 shares during the last quarter. Teamwork Financial Advisors LLC increased its position in Johnson & Johnson by 3.9% in the second quarter. Teamwork Financial Advisors LLC now owns 1,568 shares of the company’s stock worth $398,000 after buying an additional 59 shares during the period. Sonoma Allocations LLC lifted its stake in Johnson & Johnson by 25.7% in the second quarter. Sonoma Allocations LLC now owns 2,163 shares of the company’s stock valued at $548,000 after buying an additional 442 shares during the last quarter. Finally, Abner Herrman & Brock LLC lifted its stake in Johnson & Johnson by 1,864.2% in the second quarter. Abner Herrman & Brock LLC now owns 79,588 shares of the company’s stock valued at $20,213,000 after buying an additional 75,536 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.